Drug intelligence / Profile preview

TV-46046

Development stage: Unknown
Lead developer: Teva Pharmaceutical
Modality: Small Molecules
Administration: Subcutaneous

Overview

TV-46046 is an investigational long-acting contraceptive being developed by Teva. It is a subcutaneous injection formulation of medroxyprogesterone acetate, a synthetic progestin. The drug is designed to provide a contraceptive effect for up to six months per dose, which is a longer duration than existing medroxyprogesterone acetate products like Depo-subQ Provera 104. Its primary mechanism of action involves the suppression of ovulation through the activation of progesterone receptors. TV-46046 is currently in Phase 1 clinical trials to evaluate its pharmacokinetics, safety, and tolerability in healthy women of reproductive age.

Other names: medroxyprogesterone acetateMPA

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on TV-46046.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TV-46046.

Explore the full profile